Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study

Fig. 4

Differentials in time to (a) flare (i) and (b) flare (ii) according to the baseline level of serum tenascin-C. Flare (i) was defined as the need to start or escalate glucocorticoids, and flare (ii) was defined as the need to start or escalate any immunosuppressant (analysis with the Kaplan-Meier approach for survival estimation). CI confidence interval

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us